4D Molecular Therapeutics posts corporate presentation highlighting AAV gene therapy pipeline led by 4D-150 for wet AMD, DME
FDMT•Other pipeline programs
The pipeline update also highlighted 4D-710 for cystic fibrosis lung disease as fully funded, with 4D-725 for A1AT lung disease funded through IND.
Market framing and Phase 2b data
The presentation framed the retinal vascular anti-VEGF market at about USD 16 billion in 2025E, with wet AMD plus DME at about USD 14 billion.
Phase 2b PRISM data cited for 4D-150 at 3E10 vg/eye showed 1 mean supplemental injection through 1 year, implying a roughly 365+ day interval.
Corporate presentation highlights 4D-150 program
4D Molecular Therapeutics outlined a strategy centered on 4D-150, an intravitreal AAV gene therapy for wet AMD, moving into a global Phase 3 program.
Program expansion also targets diabetic macular edema, positioning 4D-150 as a potential long-duration backbone anti-VEGF therapy.
